{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:23:30Z","timestamp":1794248610109,"version":"4.9.0"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3,21]]},"abstract":"<jats:p>\n                    Fanconi anemia (FA) is an inherited disorder characterized by congenital malformations, bone marrow failure, and malignancies. Hematopoietic cell transplant (HCT) is the only proven cure for the hematological complications. FA patients have increased chromosomal instability and aberrant deoxyribonucleic acid repair and thus can only tolerate low doses of chemotherapy or radiation as part of conditioning prior to HCT. Yet, they are still prone to severe regimen related toxicities including hemorrhagic cystitis (HC) from cyclophosphamide (CY). As CYP2B6 is a primary enzyme responsible for the catalyzation of the prodrug form of CY, understanding the association between CYP2B6 genetic variants and HC in FA patients may predict which patients will be more susceptible to developing HC. A descriptive genetic association study was performed to identify genetic variants associated with HC in patients with FA who underwent HCT between 1999 and 2017. All patients received a CY-based preparative regimen and had pretransplant recipient deoxyribonucleic acid available for genomic analysis. Forty FA pediatric patients were eligible for this analysis. They had received HCT from matched sibling donors (n\u2005=\u20056) or alternative donors (n\u2005=\u200534) for marrow failure (n\u2005=\u200538) or myelodysplastic syndrome (n\u2005=\u20052). The incidence of HC was 32.5% which occurred at a median of 32 days (range 20\u2013180) after HCT. 9 patients had a concomitant viral infection (BK virus, n\u2005=\u20058 both adenovirus and BK virus, n\u2005=\u20051). No genetic variants were significantly associated with HC. The top variants were rs2279343 (g.23060A\u2005&gt;\u2005G), and rs2279344 (g.23280G\u2005&gt;\u2005A) in the CYP2B6 gene. The incidence of HC among FA patients with the rs2279343 variant was 42% (CI 22%\u201362%) compared to 20% (CI 0%\u201340%) among those without the variant (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.19). The incidence of HC among patients with the variant in rs2279344 was 40% (CI 22%\u201358%) compared to 10% (CI 0%\u201328%) among those without (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.11). No variants in our analysis were statistically associated with HC. The data suggest that CYP2B6 variants may increase the risk for HC in FA patients who received a CY based preparative therapy but these risk variants must be further evaluated in a larger population.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000041937","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:22:55Z","timestamp":1743045775000},"page":"e41937","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["CYP2B6 genetic variation in cyclophosphamide metabolism and hemorrhagic cystitis in Fanconi anemia patients undergoing allogeneic hematopoietic cell transplantation: A descriptive genetic association study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-6014","authenticated-orcid":false,"given":"Asmaa","family":"Ferdjallah","sequence":"first","affiliation":[{"name":"Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"Long","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd E.","family":"DeFor","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"Biostatistics and Informatics Core Masonic Cancer Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Hoffmann","sequence":"additional","affiliation":[{"name":"Genomics Center, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Wagner","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamala","family":"Jacobson","sequence":"additional","affiliation":[{"name":"Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret L.","family":"MacMillan","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN"},{"name":"Department of Pediatrics, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261109","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.hoc.2009.01.008","article-title":"Fanconi anemia.","volume":"23","author":"Green","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"key":"R2-20261109","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0889-8588(05)70482-2","article-title":"Molecular biology of Fanconi anemia.","volume":"11","author":"Kupfer","year":"1997","journal-title":"Hematol Oncol Clin North Am"},{"key":"R3-20261109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceb.2015.09.002","article-title":"What is the DNA repair defect underlying Fanconi anemia?","volume":"37","author":"Duxin","year":"2015","journal-title":"Curr Opin Cell Biol"},{"key":"R4-20261109","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12964-017-0195-9","article-title":"DNA damage response and cancer therapeutics through the lens of the Fanconi Anemia DNA repair pathway.","volume":"15","author":"Bhattacharjee","year":"2017","journal-title":"Cell Commun Signal"},{"key":"R5-20261109","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13578-016-0134-2","article-title":"Maintenance of genome stability by Fanconi anemia proteins.","volume":"7","author":"Palovcak","year":"2017","journal-title":"Cell Biosci"},{"key":"R6-20261109","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2015-04-639476","article-title":"Improving survival for Fanconi anemia patients.","volume":"125","author":"Gluckman","year":"2015","journal-title":"Blood"},{"key":"R7-20261109","first-page":"201","article-title":"Early effect of cyclophosphamide on oncogene expression in vivo.","volume":"12","author":"Ember","year":"1998","journal-title":"In Vivo"},{"key":"R8-20261109","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1182\/blood-2015-02-626002","article-title":"Alternative donor hematopoietic cell transplantation for Fanconi anemia.","volume":"125","author":"MacMillan","year":"2015","journal-title":"Blood"},{"key":"R9-20261109","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.bmt.1704787","article-title":"Stem cell transplantation for patients with Fanconi anemia with low-dose cyclophosphamide and antithymocyte globulins without the use of radiation therapy.","volume":"35","author":"Ayas","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"R10-20261109","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.1999.5680","article-title":"Hemorrhagic pyelitis, ureteritis, and cystitis secondary to cyclophosphamide: case report and review of the literature.","volume":"76","author":"Wong","year":"2000","journal-title":"Gynecol Oncol"},{"key":"R11-20261109","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(85)90843-8","article-title":"BK virus as cause of haemorrhagic cystitis after bone marrow transplantation.","volume":"2","author":"Rice","year":"1985","journal-title":"Lancet"},{"key":"R12-20261109","first-page":"533","article-title":"Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation.","volume":"4","author":"Miyamura","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"R13-20261109","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.bmt.1701868","article-title":"Cyclophosphamide metabolism in children with Fanconi\u2019s anaemia.","volume":"24","author":"Yule","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R14-20261109","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1046\/j.1365-2141.1996.363898.x","article-title":"Marrow transplantation for Fanconi anaemia: conditioning with reduced doses of cyclophosphamide without radiation.","volume":"92","author":"Flowers","year":"1996","journal-title":"Br J Haematol"},{"key":"R15-20261109","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/sj.bmt.1701993","article-title":"Bone marrow transplantation for patients with Fanconi anemia: reduced doses of cyclophosphamide without irradiation as conditioning.","volume":"24","author":"Medeiros","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"R16-20261109","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2141.2005.05549.x","article-title":"Low-dose cyclophosphamide conditioning for haematopoietic cell transplantation from HLA-matched related donors in patients with Fanconi anaemia.","volume":"130","author":"Zanis-Neto","year":"2005","journal-title":"Br J Haematol"},{"key":"R17-20261109","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/art.25061","article-title":"Incidence and prevention of bladder toxicity from cyclophosphamide in the treatment of rheumatic diseases: a data-driven review.","volume":"62","author":"Monach","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R18-20261109","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug-drug interactions.","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"R19-20261109","first-page":"1090","article-title":"[Cyclophosphamide and CYP2B6].","volume":"35","author":"Torimoto","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"R20-20261109","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2217\/14622416.8.7.743","article-title":"Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.","volume":"8","author":"Zanger","year":"2007","journal-title":"Pharmacogenomics"},{"key":"R21-20261109","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/leu.2008.323","article-title":"Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.","volume":"23","author":"Rocha","year":"2009","journal-title":"Leukemia"},{"key":"R22-20261109","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/ajh.21987","article-title":"The importance of correct assignment of CYP2B6 genetic variants with respect to cyclophosphamide metabolizer status.","volume":"86","author":"Helsby","year":"2011","journal-title":"Am J Hematol"},{"key":"R23-20261109","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cpt.2166","article-title":"PharmVar GeneFocus: CYP2B6.","volume":"1","author":"Desta","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R24-20261109","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1002\/cpt.1477","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for CYP2B6 and Efavirenz-containing antiretroviral therapy.","volume":"106","author":"Desta","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20261109","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/FPC.0000000000000145","article-title":"PharmGKB summary: Efavirenz pathway, pharmacokinetics.","volume":"25","author":"McDonagh","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R26-20261109","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/17474086.2016.1268048","article-title":"Hematopoietic cell transplantation in Fanconi anemia: current evidence, challenges and recommendations.","volume":"10","author":"Ebens","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R27-20261109","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/ehm.12.48","article-title":"Current clinical management of Fanconi anemia.","volume":"5","author":"Smith","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"R28-20261109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2010.08078.x","article-title":"Haematopoeitic cell transplantation for Fanconi anaemia - when and how?","volume":"149","author":"MacMillan","year":"2010","journal-title":"Br J Haematol"},{"key":"R29-20261109","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.bbmt.2017.11.031","article-title":"Comparable outcomes after HLA-matched sibling and alternative donor hematopoietic cell transplantation for children with Fanconi anemia and severe aplastic anemia.","volume":"24","author":"Ebens","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R30-20261109","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.bbmt.2015.06.012","article-title":"Second allogeneic hematopoietic cell transplantation for patients with Fanconi anemia and bone marrow failure.","volume":"21","author":"Ayas","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"R31-20261109","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/bjh.12634","article-title":"Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi anaemia.","volume":"164","author":"Mitchell","year":"2014","journal-title":"Br J Haematol"},{"key":"R32-20261109","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2006-07-036657","article-title":"Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia.","volume":"109","author":"Wagner","year":"2007","journal-title":"Blood"},{"key":"R33-20261109","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1365-2141.2009.07828.x","article-title":"Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.","volume":"147","author":"Smith","year":"2009","journal-title":"Br J Haematol"},{"key":"R34-20261109","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/sj.bmt.1705960","article-title":"Hematopoietic stem cell transplantation in childhood inherited bone marrow failure syndrome.","volume":"41","author":"Gluckman","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"R35-20261109","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.bbmt.2007.05.015","article-title":"Results of unrelated cord blood transplant in Fanconi anemia patients: risk factor analysis for engraftment and survival.","volume":"13","author":"Gluckman","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"R36-20261109","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.bbmt.2008.06.020","article-title":"HLA-matched sibling hematopoietic stem cell transplantation for Fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens.","volume":"14","author":"Pasquini","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"R37-20261109","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/pbc.20538","article-title":"Successful engraftment without radiation after fludarabine-based regimen in Fanconi anemia patients undergoing genotypically identical donor hematopoietic cell transplantation.","volume":"46","author":"Tan","year":"2006","journal-title":"Pediatr Blood Cancer"},{"key":"R38-20261109","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0090-4295(82)90633-1","article-title":"Prevention of cyclophosphamide-induced hemorrhagic cystitis.","volume":"20","author":"Droller","year":"1982","journal-title":"Urology"},{"key":"R39-20261109","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/(SICI)1097-0258(19970430)16:8<901::AID-SIM543>3.0.CO;2-M","article-title":"Non-parametric inference for cumulative incidence functions in competing risks studies.","volume":"16","author":"Lin","year":"1997","journal-title":"Stat Med"},{"key":"R40-20261109","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/FPC.0b013e32833947c2","article-title":"PharmGKB summary: very important pharmacogene information for CYP2B6.","volume":"20","author":"Thorn","year":"2010","journal-title":"Pharmacogenet Genomics"},{"key":"R41-20261109","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/dmd.31.4.398","article-title":"Functional characterization of cytochrome P450 2B6 allelic variants.","volume":"31","author":"Jinno","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"R42-20261109","doi-asserted-by":"crossref","first-page":"1002959","DOI":"10.3389\/fimmu.2022.1002959","article-title":"Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.","volume":"13","author":"Mu\u00f1iz","year":"2022","journal-title":"Front Immunol"},{"key":"R43-20261109","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1124\/dmd.111.039586","article-title":"Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.","volume":"39","author":"Ariyoshi","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"R44-20261109","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","article-title":"Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.","volume":"23","author":"Dobrinas","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R45-20261109","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/jat\/bkw135","article-title":"Tell-tale SNPs: the role of CYP2B6 in methadone fatalities.","volume":"41","author":"Ahmad","year":"2017","journal-title":"J Anal Toxicol"},{"key":"R46-20261109","doi-asserted-by":"crossref","first-page":"16775","DOI":"10.1038\/srep16775","article-title":"The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.","volume":"5","author":"Song","year":"2015","journal-title":"Sci Rep"},{"key":"R47-20261109","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2144\/03353dd02","article-title":"Quantitative real-time PCR for gene dosage determinations in microdeletion genotypes.","volume":"35","author":"Covault","year":"2003","journal-title":"Biotechniques"},{"key":"R48-20261109","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/429864","article-title":"A note on exact tests of Hardy-Weinberg equilibrium.","volume":"76","author":"Wigginton","year":"2005","journal-title":"Am J Hum Genet"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041937","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T18:01:14Z","timestamp":1794247274000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000041937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041937","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,21]]}}}